TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed HCC with serum AFP \>100ng/ml at time of screening and following most current line of therapy OR radiographic diagnosis of HCC with serum AFP \>400ng/ml at time of screening and following most current line of therapy.~* Metastatic or locally advanced, unresectable HCC~* Must have failed or not tolerated at least two (2) different anti-HCC systemic agents~* Molecular Human Leukocyte Antigen (HLA) class I allele typing confirms participant carries at least one HLA-A2 allele~* Life expectancy of at least 4 months~* Karnofsky Performance Scale greater than or equal to 70~* At least 1 measurable lesion on imaging by RECIST~* Child-Pugh A6 or better~* Absolute neutrophil count greater than or equal to 1,500/mm\^3~* Platelet count greater than or equal to 75,000/mm\^3~Exclusion Criteria:~* Clinically significant cardiac disease~* Clinically significant pre-existing illness or active infection~* Clinically significant Central Nervous System (CNS) or neural dysfunction~* Active autoimmune disease requiring therapy~* Active malignancy other than HCC with the exception of cholangiocarcinoma (CCA) or any malignancy with an expected survival ≥ 3 years without any treatment (exception: hormone/androgen-deprivation therapy) and without any organ involvement~* History of organ transplant~* Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction~* Advanced HCC involving greater than 50% of the liver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ET140203 TCells (Type: EXPERIMENTAL): ET140203 T Cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Laparoscopic Vs. Open Prostatectomy Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have undergone a prostatectomy~Exclusion Criteria:~* none

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 year old~* Not pregnant or breast feeding~* Cannabis abuse or dependence diagnosis (DSM-IV)~* Acceptance of the trial and consent signed, validated by ethic committee~* Patient affiliated to social insurance care~Exclusion Criteria:~* Contraindication to N-acetylcystein : allergic to N-acetylcystein, severe allergic illness, PHENYLCETONURIA, lactose intolerance, gastro-duodenal ulcer.~* Severe somatic disease not stabilized : diabetes, epilepsia, recent myocardial infarcts, asthma.~* Severe mental disease not stabilized : schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Experimental : N-acetylcystein (Type: EXPERIMENTAL): N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
- Placebo Comparator (Type: PLACEBO_COMPARATOR): N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have a clinical diagnosis of AD will be recruited for this study~* The participant is 50 years or older~* Written informed consent is obtained~* Participants have a clinical diagnosis of probable Alzheimer's disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria~* Subjects will have a clinical dementia rating (CDR) assessment score of ≥ 0.5 and \< 2.0~* Modified Hachinski Ischemia Scale score of ≤ 4~* For females, non-child bearing potential or negative urine and blood pregnancy test on day of 123-I MNI-168 injection~Exclusion Criteria:~* The subject has signs or symptoms of another neurodegenerative disease including Parkinson's disease, diffuse Lewy body dementia, or history of significant cerebrovascular disease~* The subject has clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness~* The subject has any disorder that may interfere with drug absorption distribution, metabolism, or excretion (including gastrointestinal surgery)~* The subject has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease~* The subject has participated in another clinical study within the previous 30 days~* Clinically significant MRI evidence of vascular disease or alternative neurologic disorder~* Pregnancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- I 123-MNI-168 (Type: EXPERIMENTAL): None
- I123 MNI168 (Type: EXPERIMENTAL): brain imaging using I123MNI168

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects 18 to 55 years of age, inclusive.~* Have a body mass index (BMI) within the range of 18.0 to 30.0 kg/m2 and a minimum weight of at least 50.0 kg~* Current recreational polydrug users who self-report to:~  * Have used stimulants (e.g., amphetamines, cocaine, methylphenidate) for non-therapeutic purposes (i.e., for psychoactive effects) at least 10 times in the past year and at least 1 time in the 8 weeks before Screening.~ * Have at least 10 lifetime uses of drugs (e.g., opioids, sedatives) from at least 1 other class other than alcohol.~* Agree to use an approved method of contraception~* Be willing and able to abide by all study requirements and restrictions~* Additional criteria may apply~Exclusion Criteria:~* Substance or alcohol dependence within the past 2 years,~* Clinically significant medical history or illness~* Female subjects who have a positive pregnancy test, are currently pregnant or lactating, or who are planning to become pregnant within 30 days of last study drug administration.~* Donation or loss of more than 500 mL whole blood within 30 days preceding the Screening visit.~* Additional criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): Placebo oral tablet and Placebo oral capsule
- Treatment B (Type: EXPERIMENTAL): Tozadenant 120 mg
- Treatment C (Type: EXPERIMENTAL): Tozadenant 240 mg
- Treatment D (Type: EXPERIMENTAL): Tozadenant 480 mg
- Treatment E (Type: ACTIVE_COMPARATOR): d-amphetamine 20 mg
- Treatment F (Type: ACTIVE_COMPARATOR): d-amphetamine 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Observation Study of the Hydroxylapatite-coated SL-PLUS™ Hip Shaft

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary total hip endoprosthesis of the side affected (unilateral or bilateral)~* Patient shall be provided with a HA-coated SL-PLUS™ stem~* Patient has no general medical contraindications regarding the surgery~* Signed informed consent form for the participation in the study~* X-ray examinations are possible~* Patient is willing to participate in the post-operative follow-up program~* Age: 18-75 years~Exclusion Criteria:~* Previous failed hip joint surgery (endoprosthesis) of the side affected~* Previous infections in the joint affected; systemic infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- SL-PLUS™ hydroxylapatite coated cement free hip stem (Type: None): Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Sarcopenia in Hepatobiliary Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* hepatobiliary surgery~* scheduled surgery~* oral consent~Exclusion Criteria:~* pregnancy~* patient under low protection~* emergency surgery~* hepatic encephalopathy stage II, III and IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transfer Strategy in an Oocyte Donation Programme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients under their first or second cycle of a synchronous (fresh) oocyte donation cycle.~Exclusion Criteria:~* Preimplantation genetic screening or diagnosis cycles.~* Patients with strict blastocyst-stage embryo transfer indication by the couple's treating physician.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Blastocyst-stage embryo transfer strategy (Type: EXPERIMENTAL): None
- Cleavage-stage embryo transfer strategy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Lifestyle, Exercise and Diet: The LEAD Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meeting criteria for subjective cognitive impairment (1 through 5 below)~  1. Answer Yes to both following questions:~     1. Do you feel like your memory or thinking is becoming worse?~    2. Does this concern you?~ 2. Have a delayed recall score on 1 paragraph of the Logical Memory test (Wechsler Memory Scale, maximum score 25) above the education-adjusted cut-offs:~     * ≥9 for 16+ years of education;~    * ≥5 for 8-15 years of education;~    * ≥3 for 0-7 years of education.~ 3. Have a Montreal Cognitive Assessment (MoCA) total score of 20 and over (≥20/30).~ 4. Have a delayed recall score on the CERAD word list of 5 and over (≥5).~ 5. Have a global Clinical Dementia Rating score (CDR) equal to 0.5 or less (≤0.5).~* ≥2 vascular risk factors (overweight (BMI\>25), T2DM, hypercholesterolemia or hypertension),~* Consuming a poor quality diet (at least median or below on number of servings of vegetable, fruit, fish and nuts based on Canadian consumption patterns in older adults)~* Reasonably sedentary (less than 75min per week of moderate - vigorous intensity physical activity)~* Be available for the whole intervention (6 months) and a 12- month follow-up visit~* English speaking~Exclusion Criteria:~* The presence of significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease, and other rarer brain illnesses.~* Ongoing alcohol or drug abuse that in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.~* Subject does not have a study partner who can provide corroborative information.~* Symptomatic stroke within the previous year.~* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure.~* Major surgery within last 2 months.~* History of intracranial surgery~* Serious comorbid condition that, in the opinion of the study investigator, is likely to result in death within a year.~* High performance athletes

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exercise plus Nutrition (Type: EXPERIMENTAL): 6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
- Exercise (Type: ACTIVE_COMPARATOR): Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* kidney transplant recipients~* kidney/pancreas transplant recipients~* age 18-80~Exclusion Criteria:~* inability to return for follow-up visits~* multiple organ transplant other than listed above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Recipients of Kidney Transplant (Type: None): Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects are fully eligible for and have completed the AMYPRED (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.~(See https://clinicaltrials.gov/ct2/show/NCT04828122)~* Subject consents to take part in FUTURE extension study.~Exclusion Criteria:~* Subject hasn't completed the full visit day in the AMYPRED study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: MCI amyloid positive (Type: None): * Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's or Mild Alzheimer's Dementia~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 2: MCI amyloid negative (Type: None): * Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 3: CN amyloid positive (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)
- Arm 4: CN amyloid negative (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18 years~2. Clinical need for percutaneous coronary intervention using either a Xience, Promus Element, or Resolute Integrity drug-eluting stent using optical coherence tomography optimization~3. Native coronary artery de novo lesion with ≥70% angiographic percent diameter stenosis by visual estimation~4. Target vessel reference diameter between 2.5 and 4.0 mm by visual estimate~5. Target lesion ≤28 mm in length by visual estimate~6. Agree to participate and provide informed consent~Exclusion Criteria:~1.Presentation with acute ST-elevation myocardial infarction (defined as electrocardiographic (ECG) ST-elevation ≥ 2 mm in 2 or more contiguous ECG leads along with symptoms compatible with ischemia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Xience EES (Type: ACTIVE_COMPARATOR): This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
- Resolute Integrity ZES (Type: ACTIVE_COMPARATOR): This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
- Promus Element EES (Type: ACTIVE_COMPARATOR): This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 18 to 79~* booked for urgent or elective colon surgery undergoing a left, right, or transverse hemicolectomy via laparotomy~Exclusion Criteria:~* patients requiring emergency surgery~* pregnant subjects or those who might be pregnant~* subjects allergic to lidocaine, ketamine, morphine, naproxen, or acetaminophen~* subjects with epidural analgesia~* subjects unable to understand and implement a Patient-Controlled Intravenous Analgesia system~* subjects who do not know English well enough to understand the consent form and assessments~* subjects with known hepatic or renal failure or cardiac dysrhythmias or atrioventricular block~* patients with pre-existing functional bowel motility disorders including Crohn's disease and ulcerative colitis~* daily use of laxatives, inability to have a bowel movement without laxatives, use of suppositories or enemas on a daily basis, or use of antimotility agents~* patients with Parkinson's disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is at least 50 years of age.~* The subjects' general health is adequate to comply with study procedures.~* The subject has been scheduled for a shunt placement procedure for the treatment of NPH.~Exclusion Criteria:~* The subject has a contraindication for MRI or PET.~* The subject is pregnant or lactating.~* The subject has a known or suspected hypersensitivity/allergy to \[18F\]flutemetamol or to any of the excipients.~* The subject has participated in any clinical study using an investigational agent within 30 days of dosing.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues